NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $9.15 +0.07 (+0.77%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$9.14 -0.01 (-0.07%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About OptimizeRx Stock (NASDAQ:OPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get OptimizeRx alerts:Sign Up Key Stats Today's Range$8.89▼$9.3150-Day Range$7.17▼$9.3752-Week Range$4.54▼$22.25Volume77,098 shsAverage Volume177,307 shsMarket Capitalization$172.39 millionP/E Ratio39.78Dividend YieldN/APrice Target$11.57Consensus RatingModerate Buy Company Overview OptimizeRx Corporation (NASDAQ: OPRX) is a digital health and life sciences technology company that helps pharmaceutical and biotechnology companies connect with healthcare professionals and patients. Its platform supports prescription-related communications, treatment access, affordability, adherence and patient engagement throughout the medication journey. The company provides solutions that can be integrated into electronic health records and other healthcare workflows. Its offerings include point-of-care messaging for healthcare professionals, patient support and savings programs, medication access tools, and data and analytics services designed to help life sciences companies communicate with relevant audiences and understand engagement. OptimizeRx was founded in 2006 and has primarily served the U.S. healthcare market, working with pharmaceutical manufacturers, healthcare providers and patients. The company is led by co-founder and Chief Executive Officer William Febbo. Its business focuses on using digital communications and healthcare data to improve connections among life sciences companies, clinicians and patients.AI Generated. May Contain Errors. Read More OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreOPRX MarketRank™: 3.31768178159 of 5 starsOptimizeRx scored higher than 66% of companies evaluated by MarketBeat, and ranked 248th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialOptimizeRx has a consensus price target of $11.57, representing about 26.5% upside from its current price of $9.15.Amount of Analyst CoverageOptimizeRx has only been the subject of 4 research reports in the past 90 days.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth34.69% Earnings GrowthEarnings for OptimizeRx are expected to grow by 34.69% in the coming year, from $0.49 to $0.66 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is 39.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.39.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is 39.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.33.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 1.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.41% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 5.77.Change versus previous monthShort interest in OptimizeRx has recently increased by 10.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for OptimizeRx this week, compared to 2 articles on an average week. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have not sold or bought any company stock.Percentage Held by Insiders7.50% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OPRX Stock News HeadlinesOptimizerx Corp (OPRX)October 23 at 1:01 PM | insidermonkey.comTrade Desk Integration and Programmatic Capabilities Drive OptimizeRx’s (OPRX) Q4 CatalystOctober 22 at 10:06 AM | finance.yahoo.comThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for more than a decade. A federal filing may outline Musk's next major move: an AI network of up to a million satellites powered by the sun. James Altucher says this supplier holds the piece Musk doesn't own.October 25 at 1:00 AM | Paradigm Press (Ad)OptimizeRx Corp. (NASDAQ:OPRX) Stock Has Average Price Target of $11.57October 20, 2026 | americanbankingnews.comOptimizeRx Corp. And The Trade Desk Bring Net New Authenticated HCP Reach To The Trade Desk Through OpenPathSeptember 22, 2026 | marketscreener.comMOptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPathSeptember 22, 2026 | globenewswire.comOptimizeRx: Gross Margin Gains And Improved Long-Term OutlookSeptember 18, 2026 | seekingalpha.comOptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience IntelligenceSeptember 14, 2026 | globenewswire.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $12.26 at the start of the year. Since then, OPRX shares have decreased by 25.4% and is now trading at $9.15. How were OptimizeRx's earnings last quarter? OptimizeRx Corp. (NASDAQ:OPRX) released its quarterly earnings results on Wednesday, August, 12th. The company reported $0.16 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.11 by $0.05. The business earned $20.50 million during the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a net margin of 4.66% and a trailing twelve-month return on equity of 9.44%. Read the conference call transcript. Is OptimizeRx buying back stock? OptimizeRx's Board of Directors authorized a share repurchase program on Thursday, March 5th 2026, which allows the company to repurchase $10,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), Block (XYZ) and Palantir Technologies (PLTR). Company Calendar Last Earnings8/12/2026Today10/25/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 OPRX's financial health is in the Green zone, according to TradeSmith. OPRX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Technology Sub-IndustryHealthcare Technology Current SymbolNASDAQ:OPRX CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees105Year Founded2006Price Target and Rating Average Price Target for OptimizeRx$11.57 High Price Target$18.00 Low Price Target$7.00 Potential Upside/Downside+26.5%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$0.23 Trailing P/E Ratio39.78 Forward P/E Ratio18.67 P/E GrowthN/ANet Income$5.13 million Net Margins4.66% Pretax Margin6.84% Return on Equity9.44% Return on Assets7.11% Debt Debt-to-Equity Ratio0.14 Current Ratio5.58 Quick Ratio5.58 Sales & Book Value Annual Sales$109.43 million Price / Sales1.58 Cash Flow$0.98 per share Price / Cash Flow9.30 Book Value$6.88 per share Price / Book1.33Miscellaneous Outstanding Shares18,840,000Free Float17,423,000Market Cap$172.39 million OptionableOptionable Beta1.26 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:OPRX) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.